These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 22005648)
41. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation. Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449 [TBL] [Abstract][Full Text] [Related]
42. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Federmann B; Bornhauser M; Meisner C; Kordelas L; Beelen DW; Stuhler G; Stelljes M; Schwerdtfeger R; Christopeit M; Behre G; Faul C; Vogel W; Schumm M; Handgretinger R; Kanz L; Bethge WA Haematologica; 2012 Oct; 97(10):1523-31. PubMed ID: 22491731 [TBL] [Abstract][Full Text] [Related]
43. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527 [TBL] [Abstract][Full Text] [Related]
44. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740 [TBL] [Abstract][Full Text] [Related]
45. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970 [TBL] [Abstract][Full Text] [Related]
46. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786 [TBL] [Abstract][Full Text] [Related]
52. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959 [TBL] [Abstract][Full Text] [Related]
53. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies. Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392 [TBL] [Abstract][Full Text] [Related]
54. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study. Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556 [TBL] [Abstract][Full Text] [Related]
55. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Marks DI; Lush R; Cavenagh J; Milligan DW; Schey S; Parker A; Clark FJ; Hunt L; Yin J; Fuller S; Vandenberghe E; Marsh J; Littlewood T; Smith GM; Culligan D; Hunter A; Chopra R; Davies A; Towlson K; Williams CD Blood; 2002 Nov; 100(9):3108-14. PubMed ID: 12384406 [TBL] [Abstract][Full Text] [Related]
56. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544 [TBL] [Abstract][Full Text] [Related]
57. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies. Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958 [TBL] [Abstract][Full Text] [Related]
58. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Nakai K; Mineishi S; Kami M; Saito T; Hori A; Kojima R; Imataki O; Hamaki T; Yoshihara S; Ohnishi M; Kim SW; Ando T; Fumitoh A; Kanda Y; Makimoto A; Tanosaki R; Kanai S; Heike Y; Ohnishi T; Kawano Y; Wakasugi H; Takaue Y Transplantation; 2003 Jun; 75(12):2135-43. PubMed ID: 12829926 [TBL] [Abstract][Full Text] [Related]
59. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Saito B; Fukuda T; Yokoyama H; Kurosawa S; Takahashi T; Fuji S; Takahashi N; Tajima K; Kim SW; Mori SI; Tanosaki R; Takaue Y; Heike Y Biol Blood Marrow Transplant; 2008 Oct; 14(10):1148-1155. PubMed ID: 18804045 [TBL] [Abstract][Full Text] [Related]
60. Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation. Kreiter S; Winkelmann N; Schneider PM; Schuler M; Fischer T; Ullmann AJ; Huber C; Derigs HG; Kolbe K Bone Marrow Transplant; 2001 Jul; 28(2):157-61. PubMed ID: 11509933 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]